Navigation Links
Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
Date:6/4/2008

SF1126 is a small-molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms. In addition to inhibiting PI3 kinase, SF1126 inhibits mTOR, DNA-PK, Polo-like 1 kinases, PIM1 and CK2 - all believed to play significant roles in the control of cell survival/proliferation signals and in cancer. SF1126 is the only PI3K inhibitor demonstrated in preclinical studies to cause an oxidative stress mechanism in cancer cells, resulting in decreased proliferation and apoptosis. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is believed that inhibiting this pathway with SF1126 could resensitize the cancer cells to approved anticancer agents and lead to possible synergistic anticancer activity. Clinical combination studies with SF1126 are being planned.

About Semafore Pharmaceuticals

Semafore Pharmaceuticals is a clinical-stage drug discovery and development company focused on small-molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets.

Semafore is actively seeking partnerships or other strategic alliances to help fulfill the promise of SF1126. For more information visit the company's Web site at http://www.SemaforePharma.com .

Contacts:

Semafore Pharmaceuticals Inc.

Sandi Yurichuk

(650) 576-5769

sandi.yurichuk@semaforepharma.com

Russo Partners LLC

David Schull

(212) 845-4271

david.schull@russopartn
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
2. Semafores SF1126 Exhibits Antitumor and Antiangiogenic Activity
3. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)...  Hill-Rom Holdings, Inc. (NYSE: HRC ) ... been elected to its Board of Directors.  She most ... as well as President of Covidien,s Vascular Therapies Division ... 2010 to 2012. Ms. Enxing Seng joined ... Incorporated, where she was a founding member and executive ...
(Date:3/4/2015)... March 4, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... the t:slim® and t:flex™ Insulin Pumps, today announced the closing ... of common stock at a price to the public of ... the underwriters of their option to purchase up to an ... were offered by Tandem. BofA Merrill Lynch ...
(Date:3/4/2015)... March 4, 2015 Amgen (NASDAQ: ... declared a $0.79 per share dividend for the second ... June 5, 2015, to all stockholders of record as ... About Amgen Amgen is committed to ... serious illnesses by discovering, developing, manufacturing and delivering innovative ...
Breaking Medicine Technology:Hill-Rom Elects Stacy Enxing Seng to its Board of Directors 2Tandem Diabetes Care Announces Closing of Underwritten Public Offering of Common Stock 2Amgen Announces 2015 Second Quarter Dividend 2Amgen Announces 2015 Second Quarter Dividend 3
... 11, 2011 China Nuvo Solar Energy, Inc. (OTCQB: ... agreement with Tandem Receivable Solutions to a western distributorship. ... is committed to assisting the Company from sales through ... Tom Toland, CEO of SurgLine stated, "As ...
... 2011 Prime Therapeutics, one of the nation,s leading ... packages offering a complete spectrum of options from rich ... Reliance, comes with a net drug spend guarantee of ... costs predictable for plan sponsors," said Michael Showalter, Prime ...
Cached Medicine Technology:China Nuvo Solar Target Acquisition SurgLine Announces Agreement With Western U.S. Distributor 2China Nuvo Solar Target Acquisition SurgLine Announces Agreement With Western U.S. Distributor 3Prime Therapeutics Announces Pharmacy Offering with Guaranteed Net Spend Per Prescription 2
(Date:3/5/2015)... Dr. Jim Hu has been appointed ... NewYork-Presbyterian/Weill Cornell Medical Center and recruited as the Ronald ... College. He assumed his new role on Feb. 1. ... the use of robotic and minimally invasive surgery to ... he will lead cutting-edge clinical and research efforts in ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Hope For The ... Sporting Clay Shoot to be held at Beretta Shooting Grounds ... 2015. All proceeds from the event will benefit Hope For ... of self, restoring the family unit, and restoring hope for ... will honor our nation’s heroes through a day of clay ...
(Date:3/5/2015)... 05, 2015 Developers and plugin specialists ... announced a new transition pack entitled TranSlice Wipe for ... screen transitions with ease while maintaining a professional look,” ... Wipe is a time saver with transitions our users ... brings back split screen transitions with a new style. ...
(Date:3/5/2015)... March 05, 2015 Aureus Medical Group ... locum tenens and direct hire physician jobs, has announced ... Nebraska Academy of Family Physicians 67th Annual Meeting & ... La Vista, Nebraska. , The Annual Meeting & ... learn, networking opportunities, and an exhibition of products and ...
(Date:3/5/2015)... Anthony Grace, PhD , ... Psychology Department of Neuroscience, University of Pittsburgh, will ... Live Neuroscience, a two-day online event highlighting recent ... , titled “Dopamine System Dysregulation in the Pathophysiology ... March 18, from 9 a.m. to 10 a.m. ...
Breaking Medicine News(10 mins):Health News:Robotic Surgery Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Robotic Surgery Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Robotic Surgery Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Hope For The Warriors Announces New York Clay Shoot to Benefit Military Families 2Health News:Pixel Film Studios Released TranSlice Wipe Exclusively for Final Cut Pro X Editors 2Health News:Healthcare Staffing Agency, Aureus Medical Group, to Exhibit at the Nebraska Academy of Family Physicians Annual Meeting & Scientific Assembly 2Health News:Anthony Grace, MD, PhD, to Deliver Keynote at BioConference Live Neuroscience 2015 2Health News:Anthony Grace, MD, PhD, to Deliver Keynote at BioConference Live Neuroscience 2015 3
... June 4 Martek Biosciences,(Nasdaq: MATK ) ... DHA omega-3 for brain, eye and heart health, ... mainstream grocery retailers,across the U.S. WhiteWave Foods launched ... in 2007 and it is now the fastest,growing ...
... June 4 DTC Perspectives, Inc. is,proud to introduce ... award will,honor and recognize individuals who have made significant ... demonstrated,a record of extraordinary achievement in DTC marketing., ... up to five individuals,will be inducted and announced. The ...
... few key locations, such as work and home , , WEDNESDAY, ... track movement, a new study suggests that people are creatures ... and remaining at -- a few key locations, such as ... to analyzing human mobility appears to be more accurate, easier, ...
... of rotavirus vaccines, ISTANBUL, Turkey, June 4 ... policymakers and leading public health,professionals from 67 countries ... Istanbul, Turkey, to present new data about,rotavirus -- ... leads to death,among young children., "Regardless of ...
... supportive policies and public research dollars, the United Kingdom, ... shares of human embryonic stem cell research, according to ... the June 2008 issue Cell Stem Cell. Aaron Levine, ... book Cloning: A Beginner,s Guide, studied how countries output ...
... June 4 BasicPlus Health,Insurance of Roswell, Ga., ... with Companion Global Healthcare Inc. of Columbia, S.C., ... its most popular,limited benefit health insurance plans., ... (for,employers) and BasicPlus (for individuals) limited benefit plans ...
Cached Medicine News:Health News:Martek's life'sDHA(TM) Now Available in Rachel's(TM) Yogurt at Grocery Retailers Nationwide 2Health News:Martek's life'sDHA(TM) Now Available in Rachel's(TM) Yogurt at Grocery Retailers Nationwide 3Health News:DTC Perspectives, Inc. Announces the New DTC Hall of Fame Award 2Health News:Cell Phone Study Suggests People Are Losing Their Wanderlust 2Health News:Cell Phone Study Suggests People Are Losing Their Wanderlust 3Health News:World's Leading Health Experts Urge Countries to Use Newly Released Data to Prevent the Death of Millions of Children Due to Rotavirus 2Health News:Public funding impacts progress of human embryonic stem cell research 2Health News:Public funding impacts progress of human embryonic stem cell research 3Health News:Insurance Company Includes Global Network Option in Limited Benefit Plans 2Health News:Insurance Company Includes Global Network Option in Limited Benefit Plans 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: